NRGBiotic

NRGBiotic
Product Description

The Product - NRGBIOTIC™

PATENTED (2036), PUBLISHED CLINICAL DATA

The successful research undertaken provided for a first-in-class probiotic for the treatment of major depressive disorder, and subsequent patents in global territories, see here.

The formulation was entered into the ARTG as a listed medicine as NRGBiotic™, see here. Medlab’s goal (although unrealised, was to synthesize NRGBiotic™ compounds for formal drug approval). As a listed medicine (aka as a nutraceutical) claims with the Australian TGA included:

Supports healthy mood balance and reduces symptom occurrence of mild anxiety

Aids the synthesis of neurotransmitters and supports nervous system health

Helps balance the gut-brain axis

Enhances energy levels

Promotes healthy muscle function, improves exercise performance and post-exercise recovery.

The product is described as an orotate with 3 specific probiotic strains in exact ratios.

Read more Show less

Medlab Group PTY LTD

  • AU
  • 2024
    On CPHI since
  • 1 - 24
    Employees
Company types
Biopharmaceutical company
Primary activities
Clinical Research
Marketing Services Provider
Out-licensing specialist
View company profile
Categories
more categories Show less
Specifications
  • Details
    PATENTED for use in Mental Health Disorders with Clinical Data

    Bifidobacterium bifidum Lactobacillus acidophilus magnesium orotate Equivalent magnesium Streptococcus thermophilus ubidecarenone
  • Selling Points
    Cognitive & Mental Function; Digestive Health; 1st in class Probiotic with clinical data and patentts that positively affect the gut/brain axiz.

    Patented in multiple Western territories.
  • Supplied from
    United Kingdom
More specifications Fewer specifications
Sales Markets
Show more Show less

Medlab Group PTY LTD

  • AU
  • 2024
    On CPHI since
  • 1 - 24
    Employees
Company types
Biopharmaceutical company
Primary activities
Clinical Research
Marketing Services Provider
Out-licensing specialist
View company profile

More Products from Medlab Group PTY LTD (2)

  • NanoCelle

    Product NanoCelle

     See https://www.medlab.group/what-is-nanocelle

    NanoCelle can be deployed in many molecules to enhance absorption, and increase patient compliance whilst reducing side effects.
  • NanoCelle B12

    Product NanoCelle B12

    B12 is a water-soluble compound, thus this foundation study was to determine NanoCelle® improvement in water-soluble compounds when compared to other more traditional forms, such as tablets, liquid emulsions, capsules, and liposomes.

    Study outcomes, published, and allowed TGA to approve hieighte...

Medlab Group PTY LTD resources (2)

  • MEDLAB GROUP - out-licencing and consultancy

    News MEDLAB GROUP - out-licencing and consultancy

    Medlab Group is a private company specialising in delivery platforms, the human microbiome, and food supplement out-licencing.
    23 Mar 2024
  • NanoCelle Introductory video - 2 min 40 sec runtime

    Video NanoCelle Introductory video - 2 min 40 sec runtime

    NanoCelle® is a unique, patented delivery system with diverse applications.
    QUICK FACTS

    Improves compound solubility

    Improves absorption

    Reduces compound side effects

    By-passes 1st pass metabolism

    Improves Patient compliance

    Improved onset

    Significant in vitro and in vivo data

    RESEARCH HAS SHOWN:

    Extensive studies have been conducted, and results differ with different compounds, but over 400,000 NanoCelle® products have been dosed to patients with minimal side effects.

    In vitro characterization done in collaboration with the University of Sydney

    PK studies showed up too 5 times more compound is absorbed when compared to tablets, capsules, emulsions, and liposomes

    Bioequivalence studies showed comparable levels to tablets 10x its dose.

    Phase 1/2 studies showed safety, tolerability, and efficacy.

    RWE Studies showed safety, tolerability, and efficacy over extended periods of time

    The research portfolio showed no reported incident of CARPA.

    2024-07-22